Point-of-care tests for bladder cancer: The influencing role of hematuria

Advances in Urology

Volumn , Issue , 2011, Pages

  Hennenlotter, Joerg ^a   Huber, Severine ^a   Todenhfer, Tilman ^a   Kuehs, Ursula ^a   Schilling, David ^a   Aufderklamm, Stefan ^a   Gakis, Georgios ^a   Schwentner, Christian ^a   Stenzl, Arnulf ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855703829     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2011/937561     Document Type: Article

References (20)

1. Lotan Y., Kamat A. M., Porter M. P., Robinson V. L., Shore N., Jewett M., Schelhammer P. F., White R. D., Quale D., Lee C. T., Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology Cancer 2009 115 18 4096 4103
2. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Bhle A., Palou-Redorta J., Rouprt M., EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update European Urology 2011 59 6 997 1008
3. Shariat S. F., Karam J. A., Lotan Y., Karakiewizc P. I., Critical evaluation of urinary markers for bladder cancer detection and monitoring Reviews in Urology 2008 10 120 135
4. Lotan Y., Shariat S. F., Schmitz-Drger B. J., Sanchez-Carbayo M., Jankevicius F., Racioppi M., Minner S. J. P., Sthr B., Bassi P. F., Grossman H. B., Considerations on implementing diagnostic markers into clinical decision making in bladder cancer Urologic Oncology 2010 28 4 441 448
5. Budman L. I., Kassouf W., Steinberg J. R., Biomarkers for detection and surveillance of bladder cancer Journal of the Canadian Urological Association 2008 2 3 212 221
6. Ponsky L. E., Sharma S., Pandrangi L., Kedia S., Nelson D., Agarwal A., Zippe C. D., Screening and monitoring for bladder cancer: refining the use of NMP22 Journal of Urology 2001 166 1 75 78 (Pubitemid 32565346)
7. Raitanen M. P., Kaasinen E., Lukkarinen O., Kauppinen R., Viitanen J., Liukkonen T., Tammela T. L., Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer Urology 2001 57 4 680 684
8. Sharma S., Zippe C. D., Pandrangi L., Nelson D., Agarwal A., Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat Journal of Urology 1999 162 1 53 57 (Pubitemid 29420879)
9. Friedman G. D., Carroll P. R., Cattolica E. V., Hiatt R. A., Can hematuria be a predictor as well as a symptom or sign of bladder cancer? Cancer Epidemiology Biomarkers and Prevention 1996 5 12 993 996 (Pubitemid 26415872)
10. Pesch B., Nasterlack M., Eberle F., Bonberg N., Taeger D., Leng G., Feil G., Johnen G., Ickstadt K., Kluckert M., Wellhuer H., Stenzl A., Brning T., The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines The British Journal of Urology International 2011 108 4 546 552
11. Atsu N., Ekici S., Oge O. O., Ergen A., Haselik G, Ozen H, False-positive results of the NMP22 test due to hematuria Journal of Urology 2002 167 2 I 555 558 (Pubitemid 34074526)
12. Oge O., Kozaci D., Gemalmaz H., The BTA stat test is nonspecific for hematuria: an experimental hematuria model Journal of Urology 2002 167 3 1318 1319 (Pubitemid 34132079)
13. Sagnak L., Ersoy H., Gucuk O., Ozok U., Topaloglu H., Diagnostic value of a urine-based tumor marker for screening lower urinary tract in low-risk patients with asymptomatic microscopic hematuria Urology International 2011 87 1 35 41
14. Lotan Y., Elias K., Svatek R. S., Bagrodia A., Nuss G., Moran B., Sagalowsky A. I., Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker Journal of Urology 2009 182 1 52 58
15. Tritschler S., Scharf S., Karl A., Tilki D., Knuechel R., Hartmann A., Stief C. G., Zaak D., Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis European Urology 2007 51 2 403 408 (Pubitemid 44937800)
16. Shariat S. F., Marberger M. J., Lotan Y., Sanchez-Carbayo M., Zippe C., Ldecke G., Boman H., Sawczuk I., Friedrich M. G., Casella R., Mian C., Eissa S., Akaza H., Serretta V., Huland H., Hedelin H., Raina R., Miyanaga N., Sagalowsky A. I., Roehrborn C. G., Karakiewicz P. I., Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer Journal of Urology 2006 176 3 919 926 (Pubitemid 44160707)
17. Kinders R., Jones T., Root R., Bruce C., Murchison H., Corey M., Williams L., Enfield D., Hass G. M., Complement factor H or a related protein is a marker for transitional cell cancer of the bladder Clinical Cancer Research 1998 4 10 2511 2520 (Pubitemid 28477919)
18. Yokoyama T., Sekigawa R., Hayashi T., Horita S., Kanamuro T., Nonami Y., Sawada T., Nishikawa T., Kobayashi M., Yamaguchi Y., Ishida H., Goya N., Nakazawa H., Toma H., The clinical efficacy of Bladder Chek NMP22 in urothelial cancer Rinsho Byori 2004 52 3 199 203
19. Schwentner C., Hennenlotter J., Kuehs U., Hematuria: helpful or misleading for the early detection of transitional cell carcinomaresults from a cohort of 2008 patients Journal of Urology 2010 183 4 supplement 1
20. Barbieri C. E., Cha E. K., Chromecki T. F., Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. The British Journal of Urology International. In press